Cycle lengths and break patterns differ across compounds and goals. The values in this post are general patterns from research literature and practitioner experience, not clinical recommendations. Always follow your provider's protocol rather than internet-aggregated defaults.
If you've spent any time in peptide forums or supplier documentation, you've seen the phrase "cycle on / cycle off." Most research peptide protocols on this site have a defined cycle length followed by a recovery period — typical patterns include 4 on / 4 off for muscle peptides, 8 on / 4 off for cosmetic, 10 days on / 10–14 weeks off for longevity. This post explains why.
What "cycling" actually addresses
Three biological mechanisms drive the rationale:
1. Receptor desensitization
When a receptor is bound by its target ligand for prolonged periods, the cell down-regulates that receptor — physically pulls some of them off the cell membrane. This is a normal homeostatic response. It happens with caffeine receptors, opioid receptors, GLP-1 receptors, GHRP receptors, and most other signaling receptors.
The practical consequence: continuous high-dose stimulation produces diminishing returns. After 8–12 weeks at a maintenance dose of something like Ipamorelin, the same dose triggers progressively less GH release because there are fewer receptors to bind.
A cycle break — typically 2–4 weeks — lets the receptor density recover.
2. Pituitary feedback (for GH-releasing peptides)
For Ipamorelin, CJC-1295, Sermorelin, Tesamorelin, and other GHRH/GHRP analogs: the pituitary itself adapts to chronic stimulation. Continuous use can blunt the natural pulsatile GH release pattern. Cycle breaks let the natural pulsing pattern re-establish.
3. Cumulative side-effect risk
Some peptides have side-effect profiles that scale with cumulative exposure — particularly Melanotan II (mole darkening, blood-pressure changes), Epithalon (limited long-term safety data), and the more investigational compounds. Cycle breaks reduce cumulative exposure without sacrificing the bulk of the benefit.
Compounds that do NOT cycle
Several FDA-approved and frequently-used compounds are designed for continuous, indefinite use rather than cycles:
| Compound | Why no cycle |
|---|---|
| Semaglutide / Tirzepatide / Liraglutide | Approved for chronic weight management — designed for indefinite once-weekly use. Stopping abruptly typically reverses metabolic gains. |
| GHK-Cu (cosmetic) | Cycles are common (8–12 weeks) but not biologically required. Some users run continuously. |
| BPC-157 (acute injury) | Run for the duration of the injury (typically 4–8 weeks), stop when healed. |
The rule of thumb: FDA-approved peptide drugs follow the label, which usually means continuous use or until clinical goal achieved. Research peptides typically follow the cycle pattern.
Standard cycle patterns by class
| Peptide class | Typical cycle | Typical break | Reason |
|---|---|---|---|
| Growth hormone (Ipa, CJC, Sermo) | 8–12 weeks | 2–4 weeks | Pituitary feedback + receptor recovery |
| Healing (BPC-157, TB-500) | 4–6 weeks | 4 weeks | Diminishing returns past acute phase |
| Cosmetic (GHK-Cu) | 8–12 weeks | 2–4 weeks | Receptor recovery + assess visible change |
| Muscle (IGF-1 LR3) | 4 weeks | 4 weeks | IGF-1 receptor desensitization is fast |
| Nootropic (Semax, Selank) | 2–6 weeks | 2 weeks | Reset receptor sensitivity |
| Longevity (Epithalon) | 10 days | 4–6 months | Pulse dosing — designed as discrete cycles |
| Sexual (PT-141) | On-demand | N/A | Used acutely, no continuous protocol |
| Sexual (Melanotan II) | Loading + maintenance | After tan goal achieved | Cumulative pigmentation |
| Metabolic (MOTS-c) | 8 weeks | 4 weeks | Receptor + clinical assessment |
The protocols section of this site has 36 templates each of which encodes the cycle structure for its compound.
What "off" means during the break
A common confusion: does "cycle off" mean stop entirely, or step down?
For most research peptide protocols: stop entirely. The break period is for recovery, not maintenance. Continuing at a low dose during the supposed off-period defeats the purpose of cycling.
The exceptions:
- GLP-1 weight management protocols — never abruptly stop without provider clearance. Tapering is typically supervised.
- Multi-peptide stacks where one component cycles and another doesn't. E.g., a Wolverine Stack might cycle BPC-157 every 6 weeks but pair with TB-500 on its own schedule.
Signs you're due for a break
Even within a planned cycle, certain signals suggest stepping back:
- Plateau in benefit. The dose that worked 4 weeks ago feels like nothing now. Classic receptor desensitization signal.
- Sleep changes for GH protocols (vivid dreams, early waking) that escalate beyond the early-cycle adjustment.
- Persistent injection-site soreness even with proper rotation.
- Side effects that didn't appear early but emerge mid-cycle — often a sign of accumulated exposure.
Tracking cycles in the iOS app
The 36 protocol templates in Peptide Calculator: Dosage Log encode each compound's cycle structure. The app:
- Auto-advances dose phases week by week so you don't lose track of where you are in the cycle
- Displays days remaining in the current phase
- Sends a reminder at the start of the planned break period — no notifications during the off-cycle, just a calendar entry for when to resume
- Tracks side effects on a timeline so you can see whether the severity is settling at the current dose-step or worsening (the signal that suggests pausing)
A common-sense cycling framework
If you're on a research-peptide protocol that doesn't have a predetermined cycle structure, the conservative defaults:
- Start with 8 weeks on, 4 weeks off as your first cycle
- Track baseline measurements (weight, photos, energy levels, side-effect severity) at start and end of each week
- If the benefit plateaus before week 8, stop at the plateau — don't push to fill the calendar
- During the break, log nothing. No "maintenance dose." No "every other week." Real reset.
- Reassess at week 4 of the off-cycle. If the benefit you were chasing has fully reversed, the cycle structure was working. If it persisted, you may not need to resume at the same intensity.
Related reading
- Protocol templates — 36 cycle structures we ship
- Tracking peptide side effects — what to watch during a cycle
- The Wolverine Stack — example of a healing-cycle structure
- The Glow Stack — cosmetic-cycle structure
References
- PubMed: receptor desensitization — underlying biology
- PubMed: GHRP tolerance — specific to growth-hormone-releasing peptides
- DailyMed — for the FDA-approved peptide drugs whose labels explicitly do not call for cycling